Sugawara I, Zhang J, Li C
Mycobacterial Reference Center, The Research Institute of Tuberculosis, 3-1-24 Matsuyama, Kiyose, Tokyo 204-0022, Japan.
Indian J Exp Biol. 2009 Jun;47(6):520-2.
Seventy-four streptomycin (SM)-resistant M. tuberculosis clinical isolates were subjected to cross-resistance drug testing against two major aminoglycosides, kanamycin (KM) and amikacin (AMK). Among them, 15 clinical isolates (20.3%) were resistant to both KM and AMK. Fifteen (80%) of 19 KM-resistant isolates were AMK-resistant. Fifteen SM, KM, and AMK resistant isolates harbored rrs mutation, but only two had rrs and rpsL double mutations. Low-level SM resistance was associated with rpsL mutation, whereas high-level SM resistance was linked to rrs mutation.
对74株耐链霉素（SM）的结核分枝杆菌临床分离株进行了针对两种主要氨基糖苷类药物卡那霉素（KM）和阿米卡星（AMK）的交叉耐药性检测。其中，15株临床分离株（20.3%）对KM和AMK均耐药。19株耐KM分离株中有15株（80%）耐AMK。15株对SM、KM和AMK耐药的分离株存在rrs突变，但只有两株具有rrs和rpsL双突变。低水平SM耐药与rpsL突变有关，而高水平SM耐药与rrs突变有关。
